

MAGE-L2 (G-14): sc-164952

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens that are expressed in tumors of different histologic types and in normal testis and placenta. MAGE-L2 (MAGE-like protein 2), also known as nM15 or NDNL1 (necdin-like 1), is a 529 amino acid protein that contains one MAGE domain. Expressed in brain and placenta, MAGE-L2 is encoded by a gene that maps to human chromosome 15q11.2. Defects in the MAGE-L2 gene are linked to the development of Prader-Willi syndrome (PWS).

REFERENCES

- Jiang, Y., et al. 1998. Imprinting in Angelman and Prader-Willi syndromes. *Curr. Opin. Genet. Dev.* 8: 334-342.
- Boccaccio, I., et al. 1999. The human MAGEL2 gene and its mouse homologue are paternally expressed and mapped to the Prader-Willi region. *Hum. Mol. Genet.* 8: 2497-2505.
- Lee, S., et al. 2000. Expression and imprinting of MAGEL2 suggest a role in Prader-willli syndrome and the homologous murine imprinting phenotype. *Hum. Mol. Genet.* 9: 1813-1819.
- Lee, S., et al. 2005. Essential role for the Prader-Willi syndrome protein necdin in axonal outgrowth. *Hum. Mol. Genet.* 14: 627-637.
- Kozlov, S.V., et al. 2007. The imprinted gene Magel2 regulates normal circadian output. *Nat. Genet.* 39: 1266-1272.
- Online Mendelian Inheritance in Man, OMIM[™]. 2008. Johns Hopkins University, Baltimore, MD. MIM Number: 605283. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
- Fukuo, Y., et al. 2010. Lack of association between MAGEL2 and schizophrenia and mood disorders in the Japanese population. *Neuromolecular Med.* 12: 285-291.

CHROMOSOMAL LOCATION

Genetic locus: MAGEL2 (human) mapping to 15q11.2.

SOURCE

MAGE-L2 (G-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of MAGE-L2 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-164952 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

MAGE-L2 (G-14) is recommended for detection of MAGE-L2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for MAGE-L2 siRNA (h): sc-90089, MAGE-L2 shRNA Plasmid (h): sc-90089-SH and MAGE-L2 shRNA (h) Lentiviral Particles: sc-90089-V.

Molecular Weight of MAGE-L2: 59 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.